{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:42:27Z","timestamp":1792273347314,"version":"4.4.0"},"reference-count":49,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000866","name":"Cardiff University","doi-asserted-by":"publisher","award":["Welsh Clinical Academic Training Fellowship"],"award-info":[{"award-number":["Welsh Clinical Academic Training Fellowship"]}],"id":[{"id":"10.13039\/501100000866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"crossref","award":["ISSF3 Clinical Primer Award"],"award-info":[{"award-number":["ISSF3 Clinical Primer Award"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Clin Pathol"],"accepted":{"date-parts":[[2020,1,13]]},"published-print":{"date-parts":[[2020,9]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>An association between antibody deficiency and clozapine use in individuals with schizophrenia has recently been reported. We hypothesised that if clozapine-associated hypogammaglobulinaemia was clinically relevant this would manifest in referral patterns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective case note review of patients referred and assessed by Immunology Centre for Wales (ICW) between January 2005 and July 2018 with extraction of clinical and immunological features for individuals with diagnosis of schizophrenia-like illness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>1791 adult patients were assessed at ICW during this period; 23 patients had a psychiatric diagnosis of schizophrenia or schizoaffective disorder. Principal indications for referral were findings of low calculated globulin and immunoglobulins. Clozapine was the single most commonly prescribed antipsychotic (17\/23), disproportionately increased relative to reported use in the general schizophrenia population (OR 6.48, 95%\u2009CI: 1.79 to 23.5). Clozapine therapy was noted in 6\/7 (86%) of patients subsequently requiring immunoglobulin replacement therapy (IgRT). Marked reduction of class-switched memory B cells (CSMB) and plasmablasts were observed in clozapine-treated individuals relative to healthy age-matched controls. Clozapine duration is associated with CSMB decline. One patient discontinued clozapine, with gradual recovery of IgG levels without use of IgRT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings are consistent with enrichment of clozapine-treatment within schizophrenic individuals referred for ICW assessment over the last 13 years. These individuals displayed clinical patterns closely resembling the primary immunodeficiency common variable immunodeficiency, however appears reversible on drug cessation. This has diagnostic, monitoring and treatment implications for psychiatry and immunology teams and directs prospective studies to address causality and the wider implications for this patient group.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jclinpath-2019-206235","type":"journal-article","created":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T17:15:31Z","timestamp":1582564531000},"page":"587-592","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":34,"title":["Clinical and laboratory characteristics of clozapine-treated patients with schizophrenia referred to a national immunodeficiency clinic reveals a B-cell signature resembling common variable immunodeficiency (CVID)"],"prefix":"10.1136","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0236-1059","authenticated-orcid":false,"given":"Mark James","family":"Ponsford","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachael","family":"Steven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathyrn","family":"Bramhall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonali","family":"Wijetilleka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Carne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances","family":"McGuire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin R","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mo","family":"Moody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soha","family":"Zouwail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayyeb","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Farewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"El-Shanawany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen R A","family":"Jolles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"key":"2024111106100676000_73.9.587.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01121-6"},{"key":"2024111106100676000_73.9.587.2","doi-asserted-by":"publisher","DOI":"10.1177\/1359786810385490"},{"key":"2024111106100676000_73.9.587.3","unstructured":"Andrew A , Knapp M , McCrone P , et al . Effective interventions in schizophrenia the economic case: a report prepared for the schizophrenia Commission. London: London School of Economics and Political Science, 2012."},{"key":"2024111106100676000_73.9.587.4","unstructured":"Cooper SCM , Etherington AM , Jayakumar S . Report of the National Audit of Schizophrenia. Royal College of Psychiatrists, 2012."},{"key":"2024111106100676000_73.9.587.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2016.11.013"},{"key":"2024111106100676000_73.9.587.6","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0000000000000162"},{"key":"2024111106100676000_73.9.587.7","doi-asserted-by":"publisher","DOI":"10.1093\/schbul\/sbr202"},{"key":"2024111106100676000_73.9.587.8","doi-asserted-by":"publisher","DOI":"10.1111\/acps.12827"},{"key":"2024111106100676000_73.9.587.9","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.bp.108.051979"},{"key":"2024111106100676000_73.9.587.10","first-page":"11","article-title":"\"Schizophrenia past clozapine\": reasons for clozapine discontinuation, mortality, and alternative antipsychotic prescribing","volume":"48","author":"Mustafa","year":"2015","journal-title":"Pharmacopsychiatry"},{"key":"2024111106100676000_73.9.587.11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k5421"},{"key":"2024111106100676000_73.9.587.12","doi-asserted-by":"crossref","unstructured":"Ponsford M , Castle D , Tahir T , et al . Clozapine is associated with secondary antibody deficiency. Br J Psychiatry 2018:1\u20137.doi:10.1192\/bjp.2018.152","DOI":"10.1192\/bjp.2018.152"},{"key":"2024111106100676000_73.9.587.13","doi-asserted-by":"crossref","first-page":"l483","DOI":"10.1136\/bmj.l483","article-title":"Antibody deficiency in patients taking clozapine","volume":"48","author":"Ponsford","year":"2019","journal-title":"BMJ"},{"key":"2024111106100676000_73.9.587.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201956"},{"key":"2024111106100676000_73.9.587.15","doi-asserted-by":"crossref","unstructured":"Patel SY , Carbone J , Jolles S . The expanding field of secondary antibody deficiency: causes, diagnosis, and management. Front Immunol 2019;10.doi:10.3389\/fimmu.2019.00033","DOI":"10.3389\/fimmu.2019.00033"},{"key":"2024111106100676000_73.9.587.16","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-091744"},{"key":"2024111106100676000_73.9.587.17","unstructured":"Cooper S , Crawford M , Dicks S . Report of the second round of the National Audit of Schizophrenia (NAS2). Royal College of Psychiatrists, 2014. https:\/\/www.rcpsych.ac.uk\/improving-care\/ccqi\/national-clinical-audits\/national-clinical-audit-of-psychosis\/national-audit-schizophrenia"},{"key":"2024111106100676000_73.9.587.18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0020141","article-title":"A systematic review of the prevalence of schizophrenia","volume":"2","author":"Saha","year":"2005","journal-title":"PLoS Med"},{"key":"2024111106100676000_73.9.587.19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0020151"},{"key":"2024111106100676000_73.9.587.20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/cei.12915","article-title":"When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach","volume":"188","author":"Jolles","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"2024111106100676000_73.9.587.21","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/147.6.1100","article-title":"The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type B","volume":"147","author":"K\u00e4yhty","year":"1983","journal-title":"J Infect Dis"},{"key":"2024111106100676000_73.9.587.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.01.035"},{"key":"2024111106100676000_73.9.587.23","doi-asserted-by":"publisher","DOI":"10.1128\/CDLI.12.9.1057-1062.2005"},{"key":"2024111106100676000_73.9.587.24","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1177\/2045125316683151","article-title":"Prescribing pattern of clozapine and other antipsychotics for patients with first-episode psychosis: a cross-sectional survey of early intervention teams","volume":"7","author":"Tungaraza","year":"2017","journal-title":"Ther Adv Psychopharmacol"},{"key":"2024111106100676000_73.9.587.25","doi-asserted-by":"publisher","DOI":"10.1177\/0004563214545791"},{"key":"2024111106100676000_73.9.587.26","doi-asserted-by":"crossref","unstructured":"Taylor DM , Paton C , Kapur S . The Maudsley prescribing guidelines. Informa Healthcare, 2009.","DOI":"10.3109\/9780203092835"},{"key":"2024111106100676000_73.9.587.27","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12369"},{"key":"2024111106100676000_73.9.587.28","doi-asserted-by":"crossref","first-page":"728","DOI":"10.2174\/1389201019666180808163311","article-title":"Validation of calculated globulin (CG) as a screening test for antibody deficiency in an Italian university hospital","volume":"19","author":"Pecoraro","year":"2018","journal-title":"Curr Pharm Biotechnol"},{"key":"2024111106100676000_73.9.587.29","doi-asserted-by":"crossref","first-page":"e0155631","DOI":"10.1371\/journal.pone.0155631","article-title":"Peripheral immune cell populations associated with cognitive deficits and negative symptoms of treatment-resistant schizophrenia","volume":"11","author":"Fernandez-Egea","year":"2016","journal-title":"PLoS One"},{"key":"2024111106100676000_73.9.587.30","first-page":"38","article-title":"International consensus document (icon): common variable immunodeficiency disorders","volume":"4","author":"Bonilla","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"2024111106100676000_73.9.587.31","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1097\/ACI.0000000000000592","article-title":"Clozapine-Associated secondary antibody deficiency","volume":"19","author":"Ponsford","year":"2019","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"2024111106100676000_73.9.587.32","doi-asserted-by":"crossref","unstructured":"Schizophrenia Working Group of the Psychiatric Genomics Consortium . Biological insights from 108 schizophrenia-associated genetic loci 2014;511:421\u20137.","DOI":"10.1038\/nature13595"},{"key":"2024111106100676000_73.9.587.33","doi-asserted-by":"publisher","DOI":"10.1097\/YCO.0b013e32835d9efb"},{"key":"2024111106100676000_73.9.587.34","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.schres.2016.05.002","article-title":"Reasons for discontinuing clozapine: a cohort study of patients commencing treatment","volume":"174","author":"Legge","year":"2016","journal-title":"Schizophr Res"},{"key":"2024111106100676000_73.9.587.35","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1176\/ajp.156.11.1751","article-title":"Smoking habits, current symptoms, and premorbid characteristics of schizophrenic patients in Nithsdale, Scotland","volume":"156","author":"Kelly","year":"1999","journal-title":"Am J Psychiatry"},{"key":"2024111106100676000_73.9.587.36","doi-asserted-by":"publisher","DOI":"10.1378\/chest.13-2853"},{"key":"2024111106100676000_73.9.587.37","doi-asserted-by":"crossref","DOI":"10.1186\/1465-9921-10-108","article-title":"Increased levels of (class switched) memory B cells in peripheral blood of current smokers","volume":"10","author":"Brandsma","year":"2009","journal-title":"Respir Res"},{"key":"2024111106100676000_73.9.587.38","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s10875-016-0264-7","article-title":"Secondary antibody deficiency in glucocorticoid therapy clearly differs from primary antibody deficiency","volume":"36","author":"Wirsum","year":"2016","journal-title":"J Clin Immunol"},{"key":"2024111106100676000_73.9.587.39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.01236","article-title":"Metformin and Autoimmunity: A \"New Deal\" of an Old Drug","volume":"9","author":"Ursini","year":"2018","journal-title":"Front Immunol"},{"key":"2024111106100676000_73.9.587.40","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10072-012-1153-3","article-title":"Valproate-Induced panhypogammaglobulinemia","volume":"34","author":"Eom","year":"2013","journal-title":"Neurol Sci"},{"key":"2024111106100676000_73.9.587.41","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(75)90206-8","article-title":"Clozapine and agranulocytosis","volume":"306","author":"Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4","year":"1975","journal-title":"The Lancet"},{"key":"2024111106100676000_73.9.587.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2012.06.020"},{"key":"2024111106100676000_73.9.587.43","first-page":"205521731769872","article-title":"Enhanced disease reduction using clozapine, an atypical antipsychotic agent, and glatiramer acetate combination therapy in experimental autoimmune encephalomyelitis","volume":"3","author":"Green","year":"2017","journal-title":"Mult Scler J Exp Transl Clin"},{"key":"2024111106100676000_73.9.587.44","unstructured":"NICE . Psychosis and schizophrenia in adults: prevention and management. Available: https:\/\/www.nice.org.uk\/guidance\/cg1782014"},{"key":"2024111106100676000_73.9.587.45","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2012-202480"},{"key":"2024111106100676000_73.9.587.46","doi-asserted-by":"crossref","DOI":"10.1136\/eb-2013-101441","article-title":"Current use of second-generation antipsychotics may increase risk of pneumonia in people with schizophrenia","volume":"16","author":"Haddad","year":"2013","journal-title":"Evid Based Ment Health"},{"key":"2024111106100676000_73.9.587.47","unstructured":"Rowbottom A , Wild GD . Pru Handbook of clinical immunology. 9th edn, 2004: 103\u20134."},{"key":"2024111106100676000_73.9.587.48","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(97)70200-2"},{"key":"2024111106100676000_73.9.587.49","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2010.04206.x"}],"container-title":["Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jclinpath-2019-206235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,11]],"date-time":"2024-11-11T09:11:46Z","timestamp":1731316306000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcp.bmj.com\/lookup\/doi\/10.1136\/jclinpath-2019-206235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":49,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,8,19]]},"published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10.1136\/jclinpath-2019-206235"],"URL":"https:\/\/doi.org\/10.1136\/jclinpath-2019-206235","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/19007815","asserted-by":"object"}]},"ISSN":["0021-9746","1472-4146"],"issn-type":[{"value":"0021-9746","type":"print"},{"value":"1472-4146","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]}}}